Furosemide is a medication classified as a loop diuretic (often called a 'water pill') and is a therapeutic agent applied in addressing conditions marked by increased physiological stress due to excess fluid retention.

The main therapeutic domain for furosemide is to provide support that helps ease the overall symptom burden associated with edema—or swelling—which is symptoms related to systemic imbalance where excess fluid builds up in body tissues. This fluid buildup is applied in addressing conditions characterized by periods of heightened symptoms such as congestive heart failure, liver disease (like cirrhosis), and certain kidney diseases (including nephrotic syndrome). Its application offers symptomatic relief that helps patients cope more steadily.

The medication is relevant in contexts involving heightened systemic burden across several conditions, including edema associated with congestive heart failure, liver cirrhosis, nephrotic syndrome, and conditions presenting with high blood pressure.

Quick Fact: Relief for Fluid Retention

Furthermore, furosemide may assist with the treatment of hypertension (high blood pressure), either alone or in combination with other antihypertensive agents. Its use may assist with maintaining functional stability and supports general well-being during symptomatic phases. Its use is considered relevant for easing the symptoms of fluid retention and high blood pressure. The medication may be used to help with symptoms that interfere with daily comfort.

Regulatory References

1. NIH MedlinePlus Drug Information on Furosemide

Eligibility for Furosemide Use: Official Regulatory Status

Furosemide is approved for use in adults and pediatric patients to treat fluid retention (edema), and in adults for hypertension. Eligibility is strictly governed by a patient’s medical status, with several conditions and populations categorized as restricted or contraindicated by regulatory bodies.

Age and Physiological Restrictions

Use in pregnant women is restricted and should occur only if the benefit clearly outweighs the potential risk. Breastfeeding women are generally advised against using Furosemide as it is excreted in breast milk and may inhibit lactation. Use in premature infants is subject to a specific maximum dose and requires monitoring for certain kidney complications. Older adults require caution due to an increased risk of dehydration and vascular complications from fluid loss.

Interactions with other medicines and products

The official regulatory documents define the Furosemide interaction profile through strict constraints aimed at mitigating organ toxicity and plasma concentration changes.

Additive Toxicity and Formal Restriction

• Co-administration with Ethacrynic acid or Aminoglycoside antibiotics is advised against due to the documented potential for additive ototoxicity (hearing damage).
• The use of Furosemide with other nephrotoxic agents, such as Cisplatin or certain Cephalosporins, increases the risk of nephrotoxicity (kidney damage).

Exposure Modification and Hemodynamic Risk

• Furosemide significantly reduces the renal clearance of Lithium, which is documented to result in a high risk of Lithium toxicity; this combination requires severe restriction.
• Other drugs eliminated by renal tubular secretion, including high-dose Salicylates or Methotrexate, also carry a risk of increased exposure.
• Combining Furosemide with ACE inhibitors or ARBs may lead to severe hypotension and potentially acute renal failure.
• Co-administration with other electrolyte-depleting agents, such as Corticosteroids or prolonged laxative use, increases the risk of hypokalemia.

Administration Timing and Specific Constraints

A specific timing-based restriction mandates that the intake of Sucralfate and Furosemide must be separated by at least two hours to prevent documented interference with Furosemide's absorption. Furthermore, documented risks highlight that Furosemide's ototoxicity is potentiated in patients with Hypoproteinemia.

Inhibition of the NKCC2 Cotransporter

Furosemide's core mechanism is the competitive inhibition of the mathbfNa^+-K^+-2Cl^- cotransporter (NKCC2) located in the thick ascending limb of the loop of Henle. This blockade prevents the reabsorption of sodium (mathbfNa^+), chloride (mathbfCl^-), and potassium (mathbfK^+) from the forming urine back into the bloodstream. This initiates a mechanistic cascade that drives an increase in fluid excretion.

Dual Systemic and Renal Physiological Effect

The consequence of NKCC2 inhibition is the loss of electrolytes and water, resulting in an outward shift of fluid from the extracellular compartment and a reduction in systemic venous filling. Furosemide also modulates the renal environment by increasing the synthesis of prostaglandins, which contributes to systemic vasodilation. This vascular effect provides an additional, immediate mechanism that modifies circulatory dynamics, often commencing before the full diuretic response is achieved.

Mechanistic Constraints

The drug's action is fundamentally dependent on its successful delivery to the NKCC2 target via active secretion in the proximal tubule. This mechanism is physiologically constrained when factors impairing drug delivery to the tubular lumen are present, such as a significant reduction in kidney excretory function or low plasma albumin levels. Furthermore, the body's Renin-Angiotensin-Aldosterone System (RAAS) acts as a compensatory mechanism that may attempt to restore sodium and fluid volume, influencing the resulting physiological adjustments.

How Фуросемид (Furosemide) is Used: Official Administration Guidelines

Furosemide's administration is strictly governed by regulatory guidelines to ensure appropriate use, defining what form to use, how much to take, and when and how to take it. These instructions are based on official prescribing information.

Official Routes and Forms

Standard Dosing and Schedule

For adults with edema, the oral starting dose is typically 20 mg to 80 mg once daily. This dose may be repeated or gradually increased by 20 mg to 40 mg every 6 to 8 hours until the desired response is achieved, though the maximum dose is generally 600 mg/day. For initial treatment via the IV or IM route, the starting dose is 20 mg to 40 mg once, with subsequent doses administered no sooner than 2 hours after the previous dose.

Frequency and Timing: Oral doses are usually taken once a day in the morning. To avoid disruption from nocturnal urination, official guidance recommends that doses should generally not be taken late in the day (e.g., after 4:00 PM).

Administration and Population Adjustments

Intake Instructions: Oral Furosemide can be taken with or without food. For the IV injection, administration must be performed slowly, over 1 to 2 minutes, with the maximum infusion rate generally restricted to 4 mg/minute.

Special Populations: Official guidelines advise a lower initial dose (e.g., 20 mg) and more cautious adjustment for older adults due to slower elimination. For pediatric patients, the dose is calculated based on body weight (typically 1 to 2 mg/kg initial dose). In cases of severe fluid retention, the parenteral route is often used and should be switched to the oral form as soon as practical.

Research Evidence / Overview of Studies for Furosemide (Фуросемид)

Evidence for Fluid Retention Studies in Heart Conditions

Research examined the evaluation of furosemide for managing fluid retention (edema) linked to Congestive Heart Failure (CHF). The evidence base includes short-term Randomized Controlled Trials (RCTs) and larger observational studies. Researchers primarily studied outcomes related to the measurement of fluid excretion, resulting changes in body weight, and symptomatic outcomes like changes in functional capacity.

Short-term trials described rapid measurements of fluid excretion in patients with acute volume overload. Findings from long-term observational data have described patterns in patient outcomes, including measurements of re-hospitalization rates and survival. The long-term evidence in this area often used furosemide as a background therapy, and the observed patterns related to higher doses are often confounded by the severity of the patient's underlying condition.

Evidence in Fluid Retention Associated with Kidney and Liver Disease

Furosemide was studied for its application in conditions characterized by fluid retention related to renal disease (such as nephrotic syndrome) and liver cirrhosis (which can cause ascites). The research base for these indications relies on prospective studies and smaller RCTs, often examining furosemide in combination with other diuretic agents. Studies explored outcomes such as the rate of ascites reduction and overall change in body weight, with observed patterns of fluid-related changes varying based on the specific regimen studied.

What is Still Uncertain About the Research Landscape

Research has established that furosemide was studied for use in acute and chronic fluid retention, but the evidence base has several recognized limitations and gaps. Long-term effects on outcomes like survival and major cardiovascular events are not fully established in direct comparison to newer loop diuretics. Optimal dosing and administration protocols for acute care are still being explored in trials, and findings were mixed across studies. Comparative evidence is lacking for certain patient subgroups, and research describes group patterns that do not determine whether an individual will respond similarly.

Key Studies & References FUROSEMIDE Tablets and Injection: U.S. Food and Drug Administration (FDA) Drug Label/Monograph

Common questions about Фуросемид (Мифар) (FAQ)

Q: What is furosemide (Mifar) and how does it work?

Furosemide is a loop diuretic, sometimes called a "water pill." It works in the kidneys to increase the amount of salt and water that passes into the urine. This action helps to remove excess fluid from the body, which can reduce swelling (edema) and lower blood pressure.

Q: What is furosemide used for?

Furosemide is primarily used to treat fluid retention (edema) associated with conditions like congestive heart failure, liver disease, or kidney disease. It is also used to treat high blood pressure (hypertension), either alone or in combination with other blood pressure medicines.

Q: How should I take furosemide (Mifar)?

Take furosemide exactly as prescribed by your doctor. It is usually taken by mouth, with or without food. Your doctor may advise you to take it in the morning to avoid needing to urinate during the night. The dosage is highly personalized, depending on your condition and response to treatment. Do not change your dose without consulting your doctor.

Q: What are common side effects of furosemide?

Common side effects may include frequent urination, dizziness, lightheadedness (especially when standing up), and stomach upset. Furosemide can also affect your electrolyte balance, potentially causing low potassium (hypokalemia), which may be managed with supplements or diet. If you experience severe side effects, contact your doctor immediately.

Q: Can furosemide interact with other medications?

Yes, furosemide can interact with many other medicines. Key interactions include:

• Other blood pressure medicines: Can cause blood pressure to drop too low.
• Digoxin: Increases the risk of digoxin toxicity, especially with low potassium levels.
• Nonsteroidal anti-inflammatory drugs (NSAIDs, like ibuprofen): May reduce the effect of furosemide and increase the risk of kidney problems.
• Aminoglycoside antibiotics (like gentamicin): Can increase the risk of hearing loss (ototoxicity).

Always tell your doctor and pharmacist about all prescription, over-the-counter, and herbal products you are taking.

How to Store and Dispose of Furosemide

Furosemide must be stored according to official regulatory requirements to ensure its stability and safety. The medication, in both tablet and injection forms, must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Excursions outside of this range, such as freezing or refrigeration, are explicitly prohibited for certain liquid formulations. Furosemide injection is light-sensitive and requires protection from light.

Stability and Disposal

Tablet portions that are scored and broken must be used within 90 days. Any unused injection solution must be discarded. The medication must be kept out of the sight and reach of children. Disposal of all expired or unused Furosemide, including used sharps containers for injection devices, must be carried out in accordance with local requirements.